Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network 052) | Zendy

Jessica M. Fogel | Zendy; Lei Wang | Zendy; Teresa L. Parsons | Zendy; San-San Ou | Zendy; Estelle PiwowarManning | Zendy; Ying Chen | Zendy; Victor Mudhune | Zendy; Mina C. Hosseinipour | Zendy; Johnstone Kumwenda | Zendy; James Hakim | Zendy; Suwat Chariyalertsak | Zendy; Ravindre Panchia | Zendy; Ian Sanne | Zendy; Nagalingeswaran Kumarasamy | Zendy; Beatriz Grinsztejn | Zendy; Joseph Makhema | Zendy; José Henrique Pilotto | Zendy; Breno Santos | Zendy; Kenneth H. Mayer | Zendy; Marybeth McCauley | Zendy; Theresa Gamble | Zendy; Namandjé N. Bumpus | Zendy; Craig W. Hendrix | Zendy; Myron S. Cohen | Zendy; Susan H. Eshleman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network 052)

Author(s) -

Jessica M. Fogel,

Lei Wang,

Teresa L. Parsons,

San-San Ou,

Estelle PiwowarManning,

Ying Chen,

Victor Mudhune,

Mina C. Hosseinipour,

Johnstone Kumwenda,

James Hakim,

Suwat Chariyalertsak,

Ravindre Panchia,

Ian Sanne,

Nagalingeswaran Kumarasamy,

Beatriz Grinsztejn,

Joseph Makhema,

José Henrique Pilotto,

Breno Santos,

Kenneth H. Mayer,

Marybeth McCauley,

Theresa Gamble,

Namandjé N. Bumpus,

Craig W. Hendrix,

Myron S. Cohen,

Susan H. Eshleman

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit390

Subject(s) - medicine , serodiscordant , viral load , clinical trial , drug , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , pharmacology

The HIV Prevention Trials Network 052 study enrolled serodiscordant couples. Index participants infected with human immunodeficiency virus reported no prior antiretroviral (ARV) treatment at enrollment. ARV drug testing was performed retrospectively using enrollment samples from a subset of index participants. ARV drugs were detected in 45 of 96 participants (46.9%) with an undetectable viral load, 2 of 48 (4.2%) with a low viral load, and 1 of 65 (1.5%) with a high viral load (P < .0001); they were also detected in follow-up samples from participants who were not receiving study-administered treatment. ARV drug testing may be useful in addition to self-report of ARV drug use in some clinical trial settings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research